Memorandum Regarding Attachment of Doripenem Development Plan to License Agreement between Shionogi & Co., Ltd. and Peninsula Pharmaceuticals, Inc.

Contract Categories: Intellectual Property › License Agreements
Summary

Shionogi & Co., Ltd. and Peninsula Pharmaceuticals, Inc. agree to attach the Doripenem Development Plan as Appendix IV to their existing License Agreement for S-4661, originally dated July 11, 2002. This memorandum, signed on March 17, 2003, formalizes the inclusion of the development plan in accordance with a specific subsection of the License Agreement. Certain confidential information has been omitted as required by SEC regulations.

Read More Arrow
EX-10.10 13 f94960orexv10w10.txt EXHIBIT 10.10 EXHIBIT 10.10 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. Memorandum Shionogi & Co., Ltd. and Peninsula Pharmaceuticals, Inc. hereby agree to attach the Doripenem Development Plan attached hereto to the License Agreement on S-4661 dated July 11, 2002 as Appendix IV in accordance with the Subsection 3.3(b)of the License Agreement. Date: March 17th, 2003 Shionogi & Co., Ltd. Peninsula Pharmaceuticals, Inc. /s/ Takuko Yamada Sawada /s/ Dirk Thye __________________________________ _______________________________ Takuko Yamada Sawada Dirk Thye, M.D. General Manager, Senior Vice President Strategic Development Department Clinical Development Pharmaceutical Research & Development Division [*] [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.